• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immun Inflamm Dis . Reduced seasonal coronavirus incidence in high-risk population groups during the COVID-19 pandemic

tetano

Editor, Senior Moderator
Immun Inflamm Dis


. 2024 Jul;12(7):e1342.
doi: 10.1002/iid3.1342. Reduced seasonal coronavirus incidence in high-risk population groups during the COVID-19 pandemic

Aliisa Heiskanen[SUP] 1 [/SUP], Yannick Galipeau[SUP] 2 [/SUP], Julian Little[SUP] 1 [/SUP], Marc-André Langlois[SUP] 2 3 [/SUP], Curtis L Cooper[SUP] 1 4 [/SUP]



Affiliations
Abstract

Background: Epidemiological data on seasonal coronaviruses (sCoVs) may provide insight on transmission patterns and demographic factors that favor coronaviruses (CoVs) with greater disease severity. This study describes the incidence of CoVs in several high-risk groups in Ottawa, Canada, from October 2020 to March 2022.
Methods: Serological assays quantified IgG and IgM antibodies to SARS-CoV-2, HCoV-OC43, HCoV-NL63, HCoV-HKU1, and HCoV-229E. Incident infections were compared between four population groups: individuals exposed to children, transit users, immunocompromised, and controls. Associations between antibody prevalence indicative of natural infection and demographic variables were assessed using regression analyses.
Results: Transit users and those exposed to children were at no greater risk of infection compared to the control group. Fewer infections were detected in the immunocompromised group (p = .03). SARS-CoV-2 seroprevalence was greater in individuals with low income and within ethnic minorities.
Conclusions: Our findings suggest that nonpharmaceutical interventions intended to reduce SAR-CoV-2 transmission protected populations at high risk of exposure. The re-emergence of sCoVs and other common respiratory viruses alongside SARS-CoV-2 may alter infection patterns and increase the risk in vulnerable populations.

Keywords: COVID‐19; SARS‐CoV‐2; incidence; seasonal coronavirus; seroprevalence.

 
Back
Top